



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/015,274	12/11/2001	Randolf von Oepen	31698-01130	7012
35023 7590 02/08/2008 LUCE, FORWARD, HAMILTON & SCRIPPS LLP 11988 EL CAMINO REAL, SUITE 200 SAN DIEGO, CA 92130			EXAMINER HUGHES, ALICIA R	
			ART UNIT 1614	PAPER NUMBER
			MAIL DATE 02/08/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10015274	12/11/2001	VON OEPEN, RANDOLF	31698-01130

LUCE, FORWARD, HAMILTON & SCRIPPS LLP
11988 EL CAMINO REAL, SUITE 200
SAN DIEGO, CA 92130

EXAMINER

Alicia R.. Hughes

ART UNIT	PAPER
1614	20071210

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The reply filed on 26 April 2007 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): The sequence listing submitted by Applicant is technically flawed. Please refer to the attached listing of sequence errors delineating these flaws. Applicant is instructed to resubmit a technically acceptable sequence listing that may be entered into the PTO database. See 37 CFR 1.111. Since the above-mentioned reply appears to be bona fide, applicant is given ONE (1) MONTH or THIRTY (30) DAYS from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a). Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alicia Hughes whose telephone number is 571-272-6026. The examiner can normally be reached from 9:00 AM to 5:00 PM, Monday through Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel, can be reached at 571-272-0718. The fax number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Public PAIR only. For information about the PAIR system, see <http://pair-direct-uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

*attachments: Notice to Comply
Raw Sequence Listing*

Ardin H Marschel 2/4/08
ARDIN H. MARSCHEL
SUPERVISORY PATENT EXAMINER

Notice to Comply	Application No. 10/015, 274	Applicant(s) VON OEPEN, RANDOLPH	
	Examiner Alicia R. Hughes	Art Unit 1614	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-2510

For CRF Submission Help, call (571) 272-2501/2583.

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Raw Sequence Listing

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Tue May 29 08:07:01 EDT 2007

=====

Reviewer Comments:

<210> 1

<211> 9

<212> PRT

<213> unidentified

<400> 1

Invalid Response for <213>, <213> Responses can only be either Artificial, Unknown or Genus Species.

This type of errors is repeated throughout the sequence listing.

Validated By CRFValidator v 1.0.2

Application No: 10015274

Version No: 1.0

Input Set:

Output Set:

Started: 2007-05-25 20:44:30.820

Finished: 2007-05-25 20:44:30.874

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 54 ms

Total Warnings: 0

Total Errors: 0

No. of SeqIDs Defined: 17

Actual SeqID Count: 17

SEQUENCE LISTING

<110> von Oepen, Randolph
von Oepen, Randolph

<120> METHODS AND APPARATUS FOR LOCALIZED ADMINISTRATION OF INHIBITORY
MOIETIES TO A PATIENT

<130> 31698-01130

<140> 10015274

<141> 2007-05-25

<150> 10/015,274

<151> 2001-12-11

<160> 17

<170> PatentIn version 3.4

<210> 1

<211> 9

<212> PRT

<213> unidentified

<400> 1

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala

1 5

<210> 2

<211> 10

<212> PRT

<213> unidentified

<400> 2

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu

1 5 10

<210> 3

<211> 7

<212> PRT

<213> unidentified

<400> 3

Asp Tyr Lys Asp Asp Asp Lys

1 5

<210> 4

<211> 6

<212> PRT

<213> unidentified

<400> 4

His His His His His His

1 5

<210> 5

<211> 6

<212> PRT

<213> unidentified

<400> 5

Asp Thr Tyr Arg Tyr Ile

1 5

<210> 6

<211> 6

<212> PRT

<213> unidentified

<400> 6

Thr Asp Phe Tyr Leu Lys

1 5

<210> 7

<211> 5

<212> PRT

<213> unidentified

<400> 7

Arg Tyr Ile Arg Ser

1 5

<210> 8

<211> 6

<212> PRT

<213> unidentified

<400> 8

Gln Tyr Pro Ala Leu Thr

1 5

<210> 9

<211> 6

<212> PRT

<213> unidentified

<400> 9

His Thr Thr Pro His His

1 5

<210> 10

<211> 15

<212> PRT

<213> unidentified

<400> 10

Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser

1 5 10 15

<210> 11

<211> 12

<212> PRT

<213> unidentified

<400> 11

Glu Asp Gln Val Asp Pro Arg Leu Thr Asp Gly Lys

1 5 10

<210> 12

<211> 6

<212> PRT

<213> unidentified

<400> 12

Glu Tyr Met Pro Met Glu

1 5

<210> 13

<211> 6

<212> PRT

<213> unidentified

<400> 13

Glu Phe Met Pro Met Glu

1 5

<210> 14

<211> 6

<212> PRT

<213> unidentified

<400> 14

Pro Pro Glu Pro Glu Thr

1 5

<210> 15
<211> 6
<212> PRT
<213> unidentified

<400> 15

Met Asn Arg Leu Gly Lys
1 5

<210> 16
<211> 11
<212> PRT
<213> unidentified

<400> 16

Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly
1 5 10

<210> 17
<211> 11
<212> PRT
<213> unidentified

<400> 17

Gln Pro Glu Leu Ala Pro Glu Asp Pro Glu Asp
1 5 10